Dr. Agarwal's Health Care Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
AGARWALEYE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Dr. Agarwal's Health Care Limited reported strong FY2026 results with total income surging 20.9% YoY to ₹2,125 crores, crossing the ₹2,000 crore milestone for the first time. Revenue from operations grew 21.6% to ₹2,080 crores, driven by 57 new facility additions taking the network to 288 facilities across 10 countries. EBITDA increased 22.2% to ₹614 crores with margins at 28.9%, while profit after tax jumped 52.4% to ₹168 crores. The company performed 323,245 surgeries during the year (up 14.5% YoY). For Q4 FY2026, total income was ₹577 crores (up 21.2% YoY) with PAT of ₹50 crores (up 17.4% YoY). The Board also approved reallocation of ₹14.88 crore unspent IPO proceeds from issue expenses to general corporate purposes. Statutory auditors S.R. Batliboi & Associates LLP issued an unmodified opinion.
Strong all-round growth with PAT up 52% demonstrates operational leverage. The stock is likely to see positive sentiment given consistent delivery across revenue, EBITDA and profit metrics, with margin expansion also indicating improving efficiency.